• Explore /
  • Poster
  • / Genomic predictors of benefit from checkpoint inhibition in neuroendocrine carcinoma.

Genomic predictors of benefit from checkpoint inhibition in neuroendocrine carcinoma.

Abstract Poster

Authors

Patrick McGarrah

Patrick Walsh McGarrah

Mayo Clinic, Rochester, MN

Patrick Walsh McGarrah , Jennifer Gile , Alex John Liu , Aaron Scott Mansfield , Konstantinos Leventakos , Aakash Desai , Sri Harsha Tella , Bassam Bassam Sonbol , Jason S. Starr , Timothy J. Hobday , Thorvardur Ragnar Halfdanarson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

DOI

10.1200/JCO.2022.40.4_suppl.512

Abstract #

512

Poster Bd #

E3

Abstract Disclosures

Similar Posters

First Author: Anne C. Chiang

First Author: Camila Bragança Xavier

First Author: Patrick Walsh McGarrah

First Author: Kevin R Reyes